References
- Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018 Jun 1;4(6):849–856.
- Wang W, Singh M. Biological drug products: development and strategies. Wiley publisher; 2013.
- Jefferis R. Biologics: structural heterogeneity and immunogenicity. Br J Hosp Med (Lond). 2017 Aug 2;78(8):443–447.
- Blandizzi C, Meroni PL, Lapadula G. Comparing originator biologics and biosimilars: a review of the relevant issues. Clin Ther. 2017 May;39(5):1026–1039.
- Bio – Biotechnology Innovation Organization. [cited Mar 2020]. Available from: https://archive.bio.org/articles/how-do-drugs-and-biologics-differ
- Rugo HS, Rifkin RM, Declerck P, et al. Demystifying biosimilars: development, regulation and clinical use. Future Oncol. 2019 Mar;15(7):777–790.
- Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014 Aug;28(4):363–372.
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012 Mar;91(3):405–417.
- International Conference on Harmonisation (ICH). ICH Q5E comparability of biotechnological/biological products subject to changes in their manufacturing processes. [cited Mar 2020]. Available from: https://app.gxp-services.net/guidemgr/files/Q5E.pdf
- Biosimilars in the EU. Information guide for healthcare professionals. [cited Mar 2020]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
- Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 Jun;75(6):974–982.
- Thayer K. How does reverse engineering work? Globalspec. IEEE Global Spec.
- Chikofsky EJ, Cross JH II. Reverse engineering and design recovery: a taxonomy. IEEE Software. 1990;7(1):13–17.
- Gordon Y, Rigmant V. Tupolev Tu-4: Soviet Superfortress. Hinckley, U.K.: Midland; 2002.
- Eldad E. Reversing: secrets of reverse engineering. Foster City, United States: John Wiley & Sons; 2005. ISBN 978-0-7645-7481-8.
- Villaverde AF, Banga JR. Reverse engineering and identification in systems biology: strategies, perspectives and challenges. J R Soc Interface. 2013 Dec 4;11(91):20130505.
- Csete ME, Doyle JC. Reverse engineering of biological complexity. Science. 2002 Mar 1;295(5560):1664–1669.
- Kremling A, Saez-Rodriguez J. Systems biology–an engineering perspective. J Biotechnol. 2007 Apr 30;129(2):329–351.
- Bui LA, Hurst S, Finch GL, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015 May;20(Suppl 1):3–15.
- Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009 Jan;27(1):26–34.
- Eisenstein M. Bring on the biosimilars. [cited Mar 2020]. Available from: https://www.nature.com/articles/d41586-019-01401-5
- Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv14–iv29.
- Mitchell M. Determining criticality-process parameters and quality attributes part i: criticality as a continuum. BioPharm Int. 2013 Dec 01;26(12). [cited Mar 2020]. Available from: http://www.biopharminternational.com/determining-criticality-process-parameters-and-quality-attributes-part-i-criticality-continuum
- FDA. Guidance for industry, process validation: general principles and practices, revision 1. Rockville, MD; 2011 January.
- Dumont J, Euwart D, Mei B, et al. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016 Dec;36(6):1110–1122.
- Fisch I. Biosimilarity: it starts by selecting the right manufacturing cell line. [cited Mar 2020]. Available from: https://selexis.com/xpressionsblog/biosimilarity-it-starts-by-selecting-the-right-manufacturing-cell-line/
- Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther. 2012 Feb;34(2):400–419.
- Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006 Oct;24(10):1241–1252.
- Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017 Dec;114(12):2696–2705.
- EMA/CHMP/BMWP/403543/2010. Committee for medicinal products for human use (CHMP). Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies – Non-clinical and Clinical Issues. 2012 [cited Apr 2020]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf
- Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33:621–634.
- Bellinvia S, Ashraf M, Polosa R, et al. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis. Immunotherapy. 2017 Nov;9(14):1133–1142.
- EMA Guideline on similar biological medicinal products. 2014 [cited Apr 2020]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
- Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12(11):1473–1485.
- Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478.
- Edwards CJ, Bellinvia S. Biosimilars. Lupus. 2020 May;29(6):525-532. doi: 10.1177/0961203320910797.
- Bellinvia S, Cummings JRF, Ardern-Jones MR, et al. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019 Jun;33(3):241–253.
- Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open. 2016 Feb 5;2(1):e000154.
- Gastl G, Geissler D, Geissler K, et al. ASHO position on biosimilars. Memo. 2009;2(4):232–233.
- Danese S, Gomollon F. Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohn Colitis. 2013;7(7):586–589.
- Fiorino G, Girolomoni G, Lapadula G, et al. SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13(7):751–755.
- Argüelles-Arias F, Barreiro-de-Acosta M, Carballo F, et al. Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2013 Jan;105(1):37–43.
- Fonseca JE, Gonçalves J, Araújo F, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port. 2014 Jan-Mar;39(1):60–71.
- Mularczyk A, Gonciarz M, Bartnik W, et al. Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol. 2014;9(1):1–3.
- Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014 Nov 20;124(22):3191–3196.
- Trotta F, Belleudi V, Fusco D, et al. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open. 2017;7(3):e011637.
- Ingrasciotta Y, Giorgianni F, Marcianò I, et al. Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: an Italian population-based study. PLoS One. 2016;11(5):e0155805.
- Azevedo VF, Galli N, Kleinfelder A, et al. Etanercept biosimilars. Rheumatol Int. 2015 Feb;35(2):197–209.
- Jacobs I, Petersel D, Isakov L, et al. Biosimilars for the treatment of chronic inflammatory diseases: a systematic review of published evidence. BioDrugs. 2016 Dec;30(6):525–570.
- Aladul MI, Fitzpatrick RW, Chapman SR. Impact of Infliximab and Etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017 Dec;31(6):533–544.
- National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. https://www.nice.org.uk/guidance/ta375/chapter/1-Recommendations (cited Apr 2020)